Cargando…

Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2(−/−) mice and human primary sclerosing cholangitis

BACKGROUND AND AIM: Ursodeoxycholic acid (UDCA) is used to treat biliary disorders; and, bile acids alter mast cell (MC) histamine release. MCs infiltrate Mdr2(−/−) mice liver (model of Primary Sclerosing Cholangitis (PSC)). MC-derived histamine increases inflammation, hepatic stellate cell (HSC) ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Fanyin, Kennedy, Lindsey, Hargrove, Laura, Demieville, Jennifer, Jones, Hannah, Madeka, Taronish, Karstens, Allen, Chappell, Kevin, Alpini, Gianfranco, Sybenga, Amelia, Invernizzi, Pietro, Bernuzzi, Francesca, DeMorrow, Sharon, Francis, Heather
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214746/ https://www.ncbi.nlm.nih.gov/pubmed/30143751 http://dx.doi.org/10.1038/s41374-018-0101-0

Ejemplares similares

Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC)
por: Zhou, Tianhao, et al.
Publicado: (2019)

Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice
por: Kennedy, Lindsey, et al.
Publicado: (2016)

FGF1 Signaling Modulates Biliary Injury and Liver Fibrosis in the Mdr2(−/−) Mouse Model of Primary Sclerosing Cholangitis
por: O’Brien, April, et al.
Publicado: (2022)

Cannabinoid Receptor 1 Antagonism Demonstrates High Therapeutic Potential for the Treatment of Primary Sclerosing Cholangitis
por: Kennedy, Lindsey, et al.
Publicado: (2022)

A Prospective Trial of Withdrawal and Reinstitution of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis
por: Black, Dennis D., et al.
Publicado: (2019)

Knockout of α-calcitonin gene-related peptide attenuates cholestatic liver injury by differentially regulating cellular senescence of hepatic stellate cells and cholangiocytes
por: Wan, Ying, et al.
Publicado: (2019)

Serum miRNA profiles are altered in patients with primary sclerosing cholangitis receiving high-dose ursodeoxycholic acid
por: Hochberg, Jessica T., et al.
Publicado: (2023)

Secondary sclerosing cholangitis: mimics of primary sclerosing cholangitis
por: Ludwig, Daniel R., et al.
Publicado: (2022)

Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis
por: Sarcognato, Samantha, et al.
Publicado: (2021)

Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis
por: Shu, Yanyun, et al.
Publicado: (2021)

IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis
por: Tanaka, Atsushi
Publicado: (2019)

Human β-Defensin 2 in Primary Sclerosing Cholangitis
por: Chang, Cindy, et al.
Publicado: (2017)

Overlap Syndrome between Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
por: Sundaram, Sridhar, et al.
Publicado: (2018)

Primary sclerosing cholangitis.
por: Spence, R. A., et al.
Publicado: (1984)

Primary sclerosing cholangitis
por: Worthington, Joy, et al.
Publicado: (2006)

Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study
por: Cançado, Guilherme Grossi Lopes, et al.
Publicado: (2022)

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
por: Harms, Maren H, et al.
Publicado: (2020)

External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid
por: Cheung, Angela C., et al.
Publicado: (2018)

Follicular T Helper Cell Signatures in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
por: Adam, Leonie, et al.
Publicado: (2018)

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics
por: Park, Ji-Won, et al.
Publicado: (2022)

Diagnosing Biliary Strictures: Distinguishing IgG4-Related Sclerosing Cholangitis From Cholangiocarcinoma and Primary Sclerosing Cholangitis
por: Hori, Yasuki, et al.
Publicado: (2021)

Primary Sclerosing Cholangitis and Amyloid A Amyloidosis: Association or Coincidence?
por: Lacetera, Rosanna, et al.
Publicado: (2022)

Looking Into the Crystal Ball: Predicting Non-response to Ursodeoxycholic Acid in Primary Biliary Cholangitis
por: Zimmer, Vincent, et al.
Publicado: (2016)

The immunobiology of primary sclerosing cholangitis
por: Aron, Jonathan H., et al.
Publicado: (2009)

Pathogenesis of primary sclerosing cholangitis
por: Pollheimer, Marion J., et al.
Publicado: (2011)

Primary sclerosing cholangitis and pregnancy
por: Kammeijer, Casper Q., et al.
Publicado: (2011)

Sclerosing Cholangitis in Behçet's Disease
por: Ben Slama Trabelsi, Aida, et al.
Publicado: (2013)

An Overview on Primary Sclerosing Cholangitis
por: Vlăduţ, Cătălina, et al.
Publicado: (2020)

Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
por: Alomari, Mohammad, et al.
Publicado: (2019)

Overlap syndrome of primary biliary cholangitis and primary sclerosing cholangitis: two case reports
por: Yacoub, Haythem, et al.
Publicado: (2023)

Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review
por: Li, Xuan, et al.
Publicado: (2020)

Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2‐deficient mice
por: Zhou, Mei, et al.
Publicado: (2016)

Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2(-/-) mouse model of sclerosing cholangitis
por: Fuchs, Claudia D., et al.
Publicado: (2023)

Emerging Therapeutic Strategies in The Fight Against Primary Biliary Cholangitis
por: Medford, Abigail, et al.
Publicado: (2023)

Knockout of secretin receptor reduces biliary damage and liver fibrosis in Mdr2(−/−) mice by diminishing senescence of cholangiocytes
por: Zhou, Tianhao, et al.
Publicado: (2018)

Long-Term Follow-Up into Adulthood of Pediatric-Onset Primary Sclerosing Cholangitis and Autoimmune Sclerosing Cholangitis
por: Hercun, Julian, et al.
Publicado: (2022)

Secondary sclerosing cholangitis and IgG4-sclerosing cholangitis – A review of cholangiographic and ultrasound imaging
por: Möller, Kathleen, et al.
Publicado: (2022)

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis
por: Martinez-Gili, Laura, et al.
Publicado: (2023)

Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
por: Sclair, Seth N, et al.
Publicado: (2015)

Evaluation of Biliary Calprotectin as a Biomarker in Primary Sclerosing Cholangitis
por: Gauss, Annika, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vinoujdfc0up3fcsif8mi4j73g